WCG
BCLI

Weaver Consulting Group’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Weaver Consulting Group’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,623
Closed -$17.5K – 265
2025
Q2 		$17.5K Hold
15,623
– – ﹤0.01% 246
2025
Q1 		$19.7K Hold
15,623
– – 0.01% 222
2024
Q4 		$35.5K Sell
15,623
-1
-0% -$2 0.01% 219
2024
Q3 		$54K Hold
15,624
– – 0.02% 220
2024
Q2 		$79.3K Buy
15,624
+2,334
+18% +$17.5K 0.03% 201
2024
Q1 		$113K Hold
13,290
– – 0.04% 197
2023
Q4 		$54.4K Buy
13,290
+6,666
+101% +$20K 0.02% 192
2023
Q3 		$19.9K Buy
6,624
+2,310
+54% +$52.5K 0.01% 184
2023
Q2 		$133K Buy
4,314
+66
+2% +$2.73K 0.06% 180
2023
Q1 		$210K Sell
4,248
-148
-3% -$4.29K 0.1% 170
2022
Q4 		$108K Sell
4,396
-1,869
-30% -$69.9K 0.06% 173
2022
Q3 		$415K Sell
6,265
-712
-10% -$35.7K 0.24% 85
2022
Q2 		$289K Sell
6,977
-1,690
-19% -$76.1K 0.16% 126
2022
Q1 		$437K Sell
8,667
-1,700
-16% -$83.5K 0.21% 89
2021
Q4 		$622K Buy
10,367
+6,934
+202% +$341K 0.3% 59
2021
Q3 		$170K Buy
3,433
+174
+5% +$9.15K 0.09% 146
2021
Q2 		$186K Sell
3,259
-74
-2% -$3.95K 0.1% 143
2021
Q1 		$192K Buy
+3,333
New +$252K 0.12% 136

Other funds holding BCLI

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BSB
Bangor Savings Bank Bangor, Maine $1.36B AUM 19.29% 1-Year Est. Return
VWA
VSM Wealth Advisory Hunt Valley, Maryland $335M AUM 16.18% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.53B AUM 17.43% 1-Year Est. Return

Weaver Consulting Group's BCLI Position: Q3 2025 in Review

Weaver Consulting Group sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2025, closing a stake of 15,623 shares — an estimated $17.5K sold.

Weaver Consulting Group first reported a position in BCLI in Q1 2021 and held it in 18 quarters. The position peaked at $622K in Q4 2021. 5 funds tracked by Wall St. Rank hold BCLI as of Q3 2025.

  • Weaver Consulting Group reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2025 after selling out during the quarter.
  • Weaver Consulting Group sold 15,623 BRAINSTORM CELL THERAPUTC shares in Q3 2025, an estimated $17.5K.
  • Weaver Consulting Group first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2021 and held it in 18 quarters.
  • Weaver Consulting Group's BRAINSTORM CELL THERAPUTC position peaked at $622K in Q4 2021.
  • 5 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2025.

Based on Weaver Consulting Group's 13F filing for Q3 2025, filed 12 Nov 2025.